Business Wire

UT-XLEAR

Share
Nathan Jones, CEO of Xlear, Inc. Statement in Response to a Lawsuit Filed by the Department of Justice, on Behalf of the United States, Alleging That Certain Statements Made by Xlear Violated the FTC Act and the Consumer Protection Act

Today, Nathan Jones, CEO of Xlear, Inc. released this statement in response to a lawsuit filed by the Department of Justice, on behalf of the United States, alleging that certain statements made by Xlear violated the Federal Trade Commission Act and the Consumer Protection Act:

Last year, the Government published on the website of the National Institutes of Health the results of a clinical trial performed by researchers at Larkin Community Hospital, Florida. The Larkin clinical trial found people who were already sick with COVID-19, who used Xlear nasal spray—and just Xlear nasal spray—cleared the disease and tested negative in half the time of the average COVID-19 case. None of the patients developed severe cases, none required hospitalization. Now the Government is suing Xlear asserting, among other things, that when Xlear tells people about scientific studies, even ones republished by the NIH, we are somehow misleading people and making false claims. It’s nonsensical.

What is more troubling, despite the results of the Larkin trial, and despite the results of a Government-funded Random Clinical Trial done at Vanderbilt University, and despite the findings of yet another Random Clinical Trial done in Georgia, the Government refuses to tell the American people that washing your nose may significantly reduce your risks of getting a severe case of COVID-19, which could result in hospitalization and death.

At the same time, growing numbers of in vitro studies find Xlear, and its components, are: antiviral (blocks adhesion—infection—by COVID-19); virucidal (kills and/or deactivates the COVID-19 virus); and, antibacterial (help prevent pneumonia, a leading COVID-19 co-morbidity). This is real science—done and published by independent medical experts. We believe so strongly in the science we are providing links to these studies here. People should read them for themselves.

In sharp contrast to trying to protect the American public, the Government is doing all in its power to stop Xlear from simply telling the public about the science. It is profoundly ironic that the Government, which now constantly ignores science for political reasons, suggests that it is taking this action against Xlear to somehow protect the people. From what is the Government protecting Americans? From the facts. From the science. From their right to know.

Notwithstanding the Government’s litany of failures in protecting Americans from COVID-19, the Government seeks to pin blame on Xlear, a small company trying to help Americans understand there are other things that you can do that may help to provide additional layer of protection against COVID-19 for you, your friends, and your family. Get vaccinated, wear a mask, social distance, use common-sense, wash your hands—and wash your nose.

The Government tells people to wash their hands; Yet COVID-19 is an upper respiratory illness. Most COVID-19 infections start in the nose. It makes commonsense to wash your nose. People have been using nasal cleansing to fight respiratory illnesses going back thousands of years.

Xlear denies the Government’s allegations. We will vigorously defend against the Government’s case, and, in doing so, defend the science against politics, paternalism, and dogmaticism.

References:
Go , Camille Celeste, Pandav, Krunal, Sanchez-Gonzalez, Marcos A, Ferrer Gustavo, Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series (Nov. 2020), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645297/
Ferrer, Gustavo, et al, A Nasal Spray Solution of Grapefruit Seed Extract plus Xylitol Displays Virucidal Activity Against SARS-Cov-2 In Vitro, BioRxiv (Nov. 25, 2020), available at https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full ;
Cannon, Mark, et al, In Vitro Analysis of the Anti-viral Potential of nasal spray constituents against SARS-CoV-2, bioRxiv 2020.12.02.408575, available at https://www.biorxiv.org/content/10.1101/2020.12.02.408575v2.full.pdf+html ;
Ferrer, G., et al., In Vitro Analysis of the Anti-viral Potential of Nasal Spray Constituents Xylitol and Grapefruit Extract plus against SARS-CoV-2, forthcoming in Journal Virus Research;
Kimura, K., et al., Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in nonhospitalized patients with coronavirus disease 2019. Int Forum Allergy Rhinol. 2020; 10: 1325– 1328, available at https://pubmed.ncbi.nlm.nih.gov/32914928/ .
Amy Baxter, et al., Rapid initiation of nasal saline irrigation to reduce morbidity and mortality in COVID+ outpatients: a randomized clinical trial compared to a national dataset, medRxiv 2021.08.16.21262044; doi:https://doi.org/10.1101/2021.08.16.21262044 available at https://www.medrxiv.org/content/10.1101/2021.08.16.21262044v2 ;
Cegolon L, Javanbakht M, Mastrangelo G. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents [published online ahead of print, 2020 Aug 18]. Int J Hyg Environ Health. 2020;230:113605. doi:10.1016/j.ijheh.2020.113605;
Lipworth B, Chan R, RuiWen Kuo C. COVID-19: Start with the nose. J Allergy Clin Immunol. 2020;146(5):1214. doi:10.1016/j.jaci.2020.06.038; Spinelli, M. et al., Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity, The Lancet, Feb. 22, 2020, available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30982-8/fulltext ;
Radulesco T, Lechien JR, Saussez S, Hopkins C, Michel J. Safety and Impact of Nasal Lavages During Viral Infections Such as SARS-CoV-2. Ear Nose Throat J. 2021;100(2_suppl):188S-191S. doi:10.1177/0145561320950491.

Link:

ClickThru

Social Media:

https://www.facebook.com/xylitol.experts

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Global styrker sin platform i Tyrkiet med tilføjelsen af medlemsvirksomhed26.11.2025 14:49:00 CET | Pressemeddelelse

Andersen Global udvider sin tilstedeværelse i Tyrkiet, efter at Celen Corporate Property Valuation & Counseling Inc. bliver til Andersen i Tyrkiet, hvilket udvider de kompetencer, der tilbydes under Andersen-brandet i landet. Det Istanbul-baserede firma blev stiftet i 1995 og ledes af Managing Partner Guniz Celen med en bred vifte af ydelser til både nationale og internationale kunder. Med ekspertise inden for finansiering af fast ejendom, værdiansættelse af materielle og immaterielle aktiver samt formueforvaltning leverer den tyrkiske afdeling af Andersen løsninger, der understøtter komplekse finansielle beslutninger for kunder i mere end 18 lande. “Vores mission har altid været at levere løsninger på de mest komplekse udfordringer inden for ejendoms- og investeringssektoren,” sagde Guniz. “At blive en del af Andersen-brandet styrker vores kompetencer som en betroet rådgiver og giver os adgang til globale ressourcer, hvilket gør os i stand til at skabe endnu større langsigtet værdi fo

Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release

Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release

If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.

Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development26.11.2025 11:15:00 CET | Press release

Modon joins a consortium of investors to elevate Wellington International equestrian showgrounds and develop an ultra-luxury destination integrating residential, hospitality and sports assets in Wellington, Palm Beach County, FloridaStrengthens Modon’s global presence and enables knowledge exchange across large-scale mixed-use, hospitality and lifestyle developments Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/ Aerial shot of Wellington International (Photo: AETOSWire) Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championshi

Epassi Announces Leadership Transition26.11.2025 11:00:00 CET | Press release

Nickyl Raithatha to join as Group CEOPekka Rantala to remain on Board as Non-Executive Chair Epassi Group, a European leader in digital employee benefits technology, today announced that Nickyl Raithatha will join as Chief Executive Officer. Nickyl will assume the role in 2026. Pekka Rantala, who has served as CEO since September 2019, will remain on the Board as Non-Executive Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126015983/en/ Pekka Rantala and Nickyl Raithatha Over the past six years, Epassi Group has evolved from a Nordic success story into one of Europe’s leading SaaS employee benefits and wellbeing platforms. The company has expanded both its geographic footprint as well as its product portfolio, driven by a powerful combination of strong organic growth and strategic acquisitions, with backing from TA Associates and Warburg Pincus. Today it has a presence in ten countries and a team of 1,000 people. W

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye